![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Sends Complete Response Letter to Mallinckrodt
FDA Sends Complete Response Letter to Mallinckrodt
![Mallinckrodt](https://www.fdanews.com/ext/resources/test/Device_Images5/mallinckrodt.jpg?t=1583963574&width=430)
August 23, 2018
Mallinckrodt confirmed it received a complete response letter from the FDA over its new drug application for stannsoporfin, a treatment for newborns at risk of developing severe jaundice.
The drugmaker said that the FDA’s letter was not unexpected after a recent joint meeting of the Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee recommended that the drug’s risk-benefit profile does not support the NDA’s approval.
The company said it would call a meeting with the agency in the coming months to discuss potential next moves.
Upcoming Events
-
21Oct